Compare General Mills, Inc. (GIS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs TG Therapeutics Inc — how do they compare? General Mills, Inc. trades at $32.29 (market cap $17.43B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: General Mills, Inc. is far larger — about 2.1× TG Therapeutics Inc's market cap, and General Mills, Inc. pays a 7.49% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and TG Therapeutics Inc for 16 Days on average.
| GIS | TGTX | |
|---|---|---|
Market Cap | $17.43B | $8.16B |
Volume | 16,554,362 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $59.06 |
52-Week Low | $31.67 | $26.94 |
Typical Hold Time | 106 Days | 16 Days |
Enterprise Value | $30.61B | $8.37B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.59, up 2.58% today, but faces fundamental challenges with negative net income margin (-4.89%) and ROE (-10.55%) for 2026. The stock shows bearish technical signals with mixed earnings performance - missing Q4 2025 estimates but beating Q2 2026. Recent CEO transition to Dana McNabb and a $3 billion cost-saving initiative aim to stabilize operations amid declining revenue trends from $19.5B (2025) to $18.3B (2026).
The stock presents a high-yield opportunity with a $0.61 dividend, but significant risks include persistent margin pressure and rising debt-to-asset ratio (45% in 2025). Analyst consensus is cautious with 61% hold ratings, though the $36 price target suggests 10% upside. Investors should weigh the dividend stability against fundamental deterioration and leadership transition execution risks.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
